Paper authored by institute scientists sheds light that better understands colorectal cancer
A team of researchers led by Professor Ningling Kang, PhD, at The Hormel Institute, University of Minnesota, has published an ...
Saint Louis University6y
10-021 - Method of treating chronic pain
The invention relates to methods of treating pain using at least one of sphingosine kinase antagonist, S1P antagonist, or S1P receptor antagonist. The invention further relates to the use of S1P ...
FiercePharma8d
Cleanup for the IL-23 class in ulcerative colitis as new drugs 'rapidly gained significant momentum': report
AbbVie’s off-patent TNF blocker is, however, now being succeeded by cheaper biosimilars, namely Boehringer Ingelheim’s ...
Daily12d
Dr Reddy's Laboratories Gets CDSCO Panel Nod for Marketing Approval of Siponimod Tablets
New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control (CDSCO) has granted ...
Nature1y
Infections cast cloud over Novartis' MS therapy
The drug is a first-in-class immunosuppressant that binds to sphingosine-1 phosphate (S1P) receptors, which have become popular targets in biotech and big pharma. The FTY720 molecule itself ...
pharmaphorum1d
Data sets up ulcerative colitis expansion for BMS’ MS drug Zeposia
Oral sphingosine 1-phosphate (S1P) 1 and 5 receptor agonist Zeposia (ozanimod) achieved all its targets in the True North trial involving adults with moderate-to-severe ulcerative colitis ...
Medscape12d
Fingolimod for the Treatment of Relapsing Multiple Sclerosis
Sphingosine is a membrane component in all cells and constitutes 25% of the lipid in the myelin sheath. Sphingosine is phosphorylated by ubiquitously expressed sphingosine kinases. S1P regulates ...